BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B

Key Takeaways BMRN will acquire all FOLD shares for $14.50 in cash, valuing the deal at $4.8B.The deal adds Galafold and Pombiliti-Opfolda, which added $449M in sales in the first nine months of 2025.BMRN will also gain U.S. rights to a late-stage drug DMX-200 being developed for a rare kidney disease.BioMarin Pharmaceutical (BMRN) announced that it entered a definitive agreement to acquire all outstanding shares of Amicus Therapeutics (FOLD) for $14.50 per share in cash, totaling $4.8 billion.The deal, app ...